SMTI Quote, Financials, Valuation and Earnings

Daxor has a net margin of -5.85% compared to Sanara MedTech's net margin of --. Sanara MedTech's return on equity of -23.3% beat Daxor's return on equity of 1.57%.

Sanara MedTech has a consensus price target of $48.50, signalling upside risk potential of 51.61%. On the other hand Daxor has an analysts' consensus of $23.50 which suggests that it could grow by 202.45%. Given that Daxor has higher upside potential than Sanara MedTech, analysts believe Daxor is more attractive than Sanara MedTech.

Sanara MedTech has a beta of 1.470, which suggesting that the stock is 46.998% more volatile than S&P 500. In comparison Daxor has a beta of -0.059, suggesting its less volatile than the S&P 500 by 105.928%.

Sanara MedTech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Daxor offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanara MedTech pays -- of its earnings as a dividend. Daxor pays out -- of its earnings as a dividend.

Sanara MedTech quarterly revenues are $26.3M, which are larger than Daxor quarterly revenues of --. Sanara MedTech's net income of -$1.5M is higher than Daxor's net income of --. Notably, Sanara MedTech's price-to-earnings ratio is -- while Daxor's PE ratio is 25.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanara MedTech is 3.13x versus 17.80x for Daxor. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -5.85% compared to Sanara MedTech's net margin of -2.16%. Sanara MedTech's return on equity of -23.3% beat Myomo's return on equity of -48.64%.

Sanara MedTech has a consensus price target of $48.50, signalling upside risk potential of 51.61%. On the other hand Myomo has an analysts' consensus of $9.25 which suggests that it could grow by 89.55%. Given that Myomo has higher upside potential than Sanara MedTech, analysts believe Myomo is more attractive than Sanara MedTech.

Sanara MedTech has a beta of 1.470, which suggesting that the stock is 46.998% more volatile than S&P 500. In comparison Myomo has a beta of 1.548, suggesting its more volatile than the S&P 500 by 54.752%.

Sanara MedTech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanara MedTech pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Sanara MedTech quarterly revenues are $26.3M, which are larger than Myomo quarterly revenues of $12.1M. Sanara MedTech's net income of -$1.5M is lower than Myomo's net income of -$260.1K. Notably, Sanara MedTech's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanara MedTech is 3.13x versus 5.66x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Precision Optics has a net margin of -5.85% compared to Sanara MedTech's net margin of -21.42%. Sanara MedTech's return on equity of -23.3% beat Precision Optics's return on equity of -38.36%.

Sanara MedTech has a consensus price target of $48.50, signalling upside risk potential of 51.61%. On the other hand Precision Optics has an analysts' consensus of -- which suggests that it could fall by --. Given that Sanara MedTech has higher upside potential than Precision Optics, analysts believe Sanara MedTech is more attractive than Precision Optics.

Sanara MedTech has a beta of 1.470, which suggesting that the stock is 46.998% more volatile than S&P 500. In comparison Precision Optics has a beta of 0.188, suggesting its less volatile than the S&P 500 by 81.244%.

Sanara MedTech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Precision Optics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanara MedTech pays -- of its earnings as a dividend. Precision Optics pays out -- of its earnings as a dividend.

Sanara MedTech quarterly revenues are $26.3M, which are larger than Precision Optics quarterly revenues of $4.5M. Sanara MedTech's net income of -$1.5M is lower than Precision Optics's net income of -$969.7K. Notably, Sanara MedTech's price-to-earnings ratio is -- while Precision Optics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanara MedTech is 3.13x versus 1.41x for Precision Optics. Usually stocks with elevated PS ratios are considered overvalued.

Warby Parker has a net margin of -5.85% compared to Sanara MedTech's net margin of -3.61%. Sanara MedTech's return on equity of -23.3% beat Warby Parker's return on equity of -6.28%.

Sanara MedTech has a consensus price target of $48.50, signalling upside risk potential of 51.61%. On the other hand Warby Parker has an analysts' consensus of $23.50 which suggests that it could grow by 48.36%. Given that Sanara MedTech has higher upside potential than Warby Parker, analysts believe Sanara MedTech is more attractive than Warby Parker.

Sanara MedTech has a beta of 1.470, which suggesting that the stock is 46.998% more volatile than S&P 500. In comparison Warby Parker has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Sanara MedTech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Warby Parker offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanara MedTech pays -- of its earnings as a dividend. Warby Parker pays out -- of its earnings as a dividend.

Sanara MedTech quarterly revenues are $26.3M, which are smaller than Warby Parker quarterly revenues of $190.6M. Sanara MedTech's net income of -$1.5M is higher than Warby Parker's net income of -$6.9M. Notably, Sanara MedTech's price-to-earnings ratio is -- while Warby Parker's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanara MedTech is 3.13x versus 2.47x for Warby Parker. Usually stocks with elevated PS ratios are considered overvalued.